Genotyping
The Geneblitz® genotyping service offers an extensive range of assays designed to complement drug discovery, research and clinical trial programmes. Our portfolio of genotyping assays is increasing rapidly and we are always pleased to hear of your genotyping requirements. If you require an assay, which is not on our current list, then please contact us. Projects are priced on a contract research basis (daily, monthly or yearly rate) whereby we discuss with you the work required and carry it out to your specification. Please email us on sales@geneblitz.com to request further information. More details can also be found on the Contact page. Examples of service offering: i) Disease Specific Genotyping This particular Geneblitz® genotyping service specialises in SNP analyses and identification in disease specific genes or disease associated regions of the genome. Our portfolio includes analysis for cancer associated genetic polymorphisms and those markers which predict the toxicity and efficacy of chemotherapeutic drugs. Other assays involve, for example, SNP's as markers for neurological disorders. Please click here for further information on cancer genotyping assays ii) Pharmacogenetic Profiling - Drug Metabolism
The Geneblitz® service is designed to assist you with the process of understanding the genetic profiles of patients enrolled in phase I to phase IV clinical trials, by determination of DNA polymorphisms associated with the phase I and phase II enzymes. Our portfolio of pharmacogenetic genotyping assays is substantial and we would be pleased to discuss your needs with you. Please click here for details of our pharmacogenetic profiling services. Please click here for further information on drug metabolism. We also offer services such as Residual DNA, Genotyping, Forensic Testing, Gene Expression and various other services. Please click here to contact us with your requirements. We are reliable, responsive and cost effective. |





That individuals respond in a different manner to equivalent doses of the same drug is a well-known phenomenon. In mammals, the metabolism of xenobiotics is catalysed by the phase I (oxidation) and phase II (conjugation) enzyme systems.